Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerL-Y Huw, Mark R. Lackner(Zen-Noh (Japan))OncogenesisDecember 23, 201310.1038/oncsis.2013.46Cited by 89SaveCiteExport RISWatch citationsRelated PapersTargeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers|PLoS ONE|2014|36Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers|npj Precision Oncology|2025|15